Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/signaling.2.043
Chemotherapy, immunotherapy, and antiangiogenesis: Emerging trends in the comprehensive treatment of advanced gastric cancer
Yuting Ding1,#, Hao Qian1,#, Yitong Tian1, Jiaguang Zhang1, Xinyi Zhang1, Ling Ma1, Taisong Li2, Ke Jin3, Fengyuan Li4,*, Yongqian Shu1,5,*, Xiaofeng Chen1,5,6, *
- #co-first authors
- 1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- 2Department of Pharmacy, Suining People’s Hospital, Xuzhou, China
- 3Department of Oncology, Liyang People's Hospital, Liyang, China
- 4Department of General surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
- 5Gusu School, Nanjing medical University, Suzhou, China
- 6Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
Corresponding Author
Fengyuan Li, lfyuan@njmu.edu.cn
Yongqian Shu, shuyongqian@csco.org.cn
Xiaofeng Chen, chenxiaofengnjmu@163.com
Received Date: June 25, 2024
Accepted Date: August 02, 2024
Ding Y, Qian H, Tian Y, Zhang J, Zhang X, Ma L, et al. Chemotherapy, immunotherapy, and anti-angiogenesis: Emerging trends in the comprehensive treatment of advanced gastric cancer. Cell Signal. 2024;2(1):126-133.
Copyright: © 2024 Ding Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Chemotherapy, immunotherapy, anti-angiogenesis, gastric cancer, adenocarcinoma, Triplet Therapy
Recommended Articles
Immunotherapy as a treatment to confront the ongoing opioid epidemic- A review
Substance use disorders continue to be major medical and social problems worldwide. The use of opiate has grown substantially over the past three decades reaching the dimensions of a global epidemic. Current drug treatments have many limitations: long treatment times, dependency on treatment medications, relapses after treatment, high costs of treatment, and non-adherence by affected persons. Most of the available drug treatments for opiate addiction belong to the opioid family. Some worry that the availability of the drugs may simply cause substituting one opioid medication for another.
Selecting ideal combined immunotherapy for treating HCC
The discovery of proper sensitizers for immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) treatment represents a significant breakthrough in the field of cancer therapy, but it is still in initial stage [1,2].
Impact of sex on premature mortality for elderly patients with early adenocarcinoma of the esophagus or stomach
Background: In a recent study, it was shown that patients with pT1 adenocarcinoma of the esophagus or stomach have a shorter survival time compared to an age- and gender-matched group from the normal population despite curative therapy. The reasons for the loss of expected life years (YLL) can only be discussed. The aim of the present evaluation is to analyze the influence of the patients' gender on the results.
The rising tide of pancreatic adenocarcinoma: A review of risk factors, diagnostic challenges, and treatment updates
Pancreatic ductal adenocarcinoma (PAC) is an aggressive malignancy that is frequently locally invasive or widely metastatic at the time of diagnosis. As such, morbidity and mortality remain extremely high. Despite growing advances in surgical technique and medical management, the incidence and mortality rate are expected to increase over the next two decades.
Reflex ordered testing for molecular biomarkers in lung adenocarcinoma: An update
Molecular biomarker testing is essential to the work up of metastatic and advanced non-small cell lung carcinoma. Despite molecular testing guidelines proposed by the National Comprehensive Cancer Network, Association for Molecular Pathology, and many others, multiple reports continue to indicate that lung cancer patients are inadequately tested for key molecular biomarkers. Within our hospital system, reflex ordered testing of a panel of molecular biomarkers in all newly diagnosed lung adenocarcinomas was approved and implemented in 2017.